Compare TNDM & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNDM | CERT |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2013 | 2020 |
| Metric | TNDM | CERT |
|---|---|---|
| Price | $22.41 | $8.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 10 |
| Target Price | ★ $28.00 | $11.67 |
| AVG Volume (30 Days) | 2.2M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,014,736,000.00 | $418,838,000.00 |
| Revenue This Year | $8.11 | $4.18 |
| Revenue Next Year | $11.85 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.93 | ★ 8.75 |
| 52 Week Low | $11.46 | $4.45 |
| 52 Week High | $29.65 | $13.88 |
| Indicator | TNDM | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 62.62 | 63.31 |
| Support Level | $19.70 | $7.94 |
| Resistance Level | $24.23 | $9.93 |
| Average True Range (ATR) | 1.46 | 0.37 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 72.22 | 83.04 |
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.